With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1228779-96-1,3-Nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)benzenesulfonamide,as a common compound, the synthetic route is as follows.
General procedure: To a solution of 3-nitro- 4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)benzenesulfonamide (63 mg, 0.20 mmol) in DCM (20 mL) was added EDC*HC1 (58 mg, 0.30 mmol) followed by DMAP (49 mg, 0.40 mmol) at 0 C. After 10 min, Intermediate 26 (140 mg, 0.20 mmol) and N- methylmorpholine (0.07 mL, 0.60 mmol) were added and the reaction was warmed to rt. After 16 h, water was added, and the mixture was extracted with DCM. The combined organic layers were dried over Na2S04, filtered and concentrated. The crude product was purified by HPLC (10:90 to 99: 1 lOmM NH4C03H(aq.)/ CH3CN) to afford Example 1 (69 mg, 39%) as a yellow solid. NMR (300 MHz, DMSO -d6) d 11.68 (br s, 1H), 11.42 (br s, 1H), 8.58 (br s, 1H), 8.53 (s, 1H), 8.03 (d, 7=2.1 Hz, 1H), 7.77 (d, 7=8.4 Hz, 1H), 7.54-7.46 (m, 3H), 7.10-7.02 (m, 1H), 6.74-6.68 (m, 1H), 6.38 (s, 1H), 6.25 (s, 1H), 3.89-3.82 (m, 2H), 3.33-3.22 (m, 4H), 3.19-3.05 (m, 4H), 2.90 (s, 2H), 2.33 (br s, 4H), 2.29 (s, 6H), 2.05-1.95 (m, 2H), 1.95-1.82 (m, 1H), 1.69-1.57 (m, 4H), 1.32-1.18 (m, 4H), 0.82 (s, 6H).; LC/MS (ESI) m/z 858.4 [M+H]+., 1228779-96-1
As the paragraph descriping shows that 1228779-96-1 is playing an increasingly important role.
Reference£º
Patent; ZENO ROYALTIES & MILESTONES, LLC; PINCHMAN, Joseph, Robert; HUANG, Peter, Qinhua; BUNKER, Kevin, Duane; SIT, Rakesh, Kumar; SAMATAR, Ahmed, Abdi; (236 pag.)WO2019/139902; (2019); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics